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Multiple myeloma (MM) is a malignancy of plasma
cells. Genome-wide association studies have shown
that variation at 5q15 influences MM risk. Here, we
have sought to decipher the causal variant at 5q15
and themechanism bywhich it influences tumorigen-
esis. We show that rs6877329 G > C resides in a
predicted enhancer element that physically interacts
with the transcription start site of ELL2. The
rs6877329-C risk allele is associated with reduced
enhanceractivityand loweredELL2expression.Since
ELL2 is critical to the B cell differentiation process,
reduced ELL2 expression is consistent with inherited
genetic variation contributing to arrest of plasma cell
development, facilitating MM clonal expansion.
These data provide evidence for a biological mecha-
nism underlying a hereditary risk of MM at 5q15.
INTRODUCTION
Multiple myeloma (MM) is a malignancy of plasma cells primarily
localized to the bone marrow (Kyle and Rajkumar, 2004; Kyle
et al., 2007). The disease is genetically heterogeneous but can
be broadly divided into hyperdiploid MM (HRDMM) and non-
HRDMM subtypes (Gould et al., 1988; Sawyer et al., 1995;
Smadja et al., 1998). Non-HRDMM is characterized by translo-
cations of the immunoglobulin heavy chain (IgH) alleles at
14q32 with various recurrently observed genes, the significance
of which is generally considered to be increased expression of
the translocated partner gene. In contrast, HRDMM involves
trisomies of odd-numbered chromosomes.2556 Cell Reports 20, 2556–2564, September 12, 2017 ª 2017 The A
This is an open access article under the CC BY license (http://creativeAlthough the etiological basis of MM is poorly understood, it
has a significant genetic component as evidenced by a 2- to
4-fold increased risk in first-degree relatives of MM patients
(Altieri et al., 2006; Landgren et al., 2009; Vachon et al., 2009).
Our understanding of MM susceptibility has recently been trans-
formed by genome-wide association studies (GWASs), which
provide strong evidence that common genetic variation influ-
ences MM risk. So far, GWASs have identified 17 independent
risk loci, with the signal annotating elongation factor for RNA
polymerase II 2 (ELL2) at 5q15 being highly robust (Broderick
et al., 2011; Chubb et al., 2015; Mitchell et al., 2016; Swamina-
than et al., 2015). ELL2 encodes a key component of the
super-elongation complex (SEC) that drives secretory-specific
immunoglobulin (Ig) mRNA production and transcriptional regu-
lation in plasma cells (Park et al., 2014).
Here, we sought to identify the causal polymorphism(s) driving
the 5q15 genetic association with MM susceptibility as a basis
for understanding MM initiation. Our data are compatible with
the rs6877329 variant as the functional basis of the 5q15 associ-
ation, a genomic region, which through chromatin-looping inter-
action leads to the reduced expression of ELL2.RESULTS
Fine Mapping and Epigenomic Profiling of the 5q15
Locus
We analyzed previously published UK and German GWAS data-
sets totaling 3,790 case subjects and 7,304 control subjects
(Mitchell et al., 2016), genotyped on Illumina Human
OmniExpress-12 v1.0, Illumina HumanOmni1-Quadv1, and
Hap1.2M-Duo Custom arrays. To inform fine-mapping of the
5q15 risk locus, we imputed untyped genotypes in both GWASs
using the UK10K (Huang et al., 2015) and 1000 Genomes Projectuthors.
commons.org/licenses/by/4.0/).
(legend on next page)
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(The 1000 Genomes Project Consortium, 2010) as a reference.
Overall, the strongest association across all forms of MM in a
meta-analysis of the two GWAS datasets was provided by
rs11372862 (OR = 1.16, p = 3.753 105, Phet = 0.85, Figure 1A),
which is highly correlated with rs1423269 (r2 = 0.97, D’ = 0.97),
the previously reported sentinel SNP for the 5q15 risk locus.
Conditional analysis provided no evidence for additional inde-
pendently associated SNPs at 5q15. By referencing germline
whole-genome sequencing (WGS) data on 640 MM patients
analyzed as part of the CoMMpass Study (Craig et al., 2013),
we were able to confirm that the imputation captured >90% of
sequence variation (minor allele frequency [MAF] > 0.05) within
the linkage disequilibrium (LD) region encompassing
rs11372862 (i.e., pairwise r2 R 0.1) (Table S1). By analyzing
the germline exomes of 513MMcase subjects from the UKMed-
ical Research Council (MRC) MyIX and MyXI clinical trials and
1,569 UK control subjects from the UK 1958 Birth Cohort (Scales
et al., 2017), we excluded the possibility that the 5q15 associa-
tion signal is a consequence of LD with a rare disease-causing
coding variant (Table S2).
Since there is previous evidence of subtype specificity for
MM association (Weinhold et al., 2013), with the 11q13.3 asso-
ciation for MM being highly specific for t(11;14) MM, we exam-
ined whether the 5q15 association might also show evidence of
subtype specificity. Stratifying MM by subtype revealed that
risk at 5q15 was primarily associated with HRDMM
(OR = 1.26, p = 1.37 3 105, Phet = 0.52) (Figure 1B; Table
S3A). Case-only analysis also provided supportive evidence
that the rs11372862 association was mainly driven by HRDMM
(p = 0.04; Table S3B).
To gain further insight into the association, we performed an
expression quantitative trait locus (eQTL) analysis using mRNA
expression data on CD138-purified plasma cells from 841 MM
case subjects from the UK MRC MyIX trial and German-
Speaking Multiple Myeloma Multicenter Study Group (GMMG)
trials. Specifically, we used Summary data-based Mendelian
randomization (SMR) analysis to test for pleiotropy between
GWAS signal and cis-eQTL for genes within 1 Mb of the lead
SNP rs11372862 to identify a causal relationship (Zhu et al.,
2016). eQTL analysis provided evidence for differential ELL2
expression as being the basis of the 5q15 association (Figure 1C;
Figure S1). Multiple SNPs (n = 90, including rs1423269,
rs11372862, rs3777184, and rs6877329) mapping within ELL2
in strong LD essentially defined a single haplotype defining
MM risk and eQTL (Figure 1C).Figure 1. Regional Plots of Association Results of the 5q15 Locus
(A and B) The region of association maps to a 40 kb haplotype block within EL
chromosomal position (NCBI build 37 human genome) on the x axis andlog10 p v
and German GMMG trials (3,790 case subjects and 7,304 control subjects), and (
and German populations (1,363 HRDMM case subjects, 1,339 non-HRDMM case
extent of LD with the lead SNP, rs11372862 (white r2 = 0 to dark red/blue r2 = 1). R
are shown by a light blue line. The relative positions of ELL2 and C5orf27mapping
lines.
(C) Summary data-basedMendelian randomization analysis at 5q15. Upper panel
analysis (1,363 cases and 7,304 controls), diamonds represent p values for prob
from MM plasma cells from 183 MRCMyIX trial patients (GEO: GSE21349) and 65
the SMR (i.e., PSMR < 0.00833) and HEIDI (i.e. PHEIDI > 0.05) tests highlighted in red
(CDF v.17) mapping to Entrez genes.
2558 Cell Reports 20, 2556–2564, September 12, 2017The eQTL data suggest the 5q15 association with MM is likely
to bemediated by the regulation ofELL2 expression. To prioritize
candidate risk variants, we examined the SNPs in LD (r2R 0.8)
with rs11372862 within regulatory elements defined by B cell-
specific DNase I hypersensitivity (DNaseI HS) and promoter/
enhancer-associated histone marks (Figure 2). Six SNPs each
correlated with rs11372862 localize within an 8 kb active
enhancer region (Table S4), supported by ChromHMM, open
chromatin analysis (DNaseI HS), as well as H3K4Me1,
H3K4Me3, and H3K27Ac peaks in GM12878 (ENCODE Project
Consortium, 2012), the MM cell line KMS11, and the plasma
cell leukemia cell lines (PCL) JJN3 and L363.
Physical interactions between regulatory elements and
promoters play a major role in regulating gene expression
(Mifsud et al., 2015; Rao et al., 2014). Following our observation
that six correlated SNPs localize within an enhancer element, we
interrogated whether this genomic region physically interacts
with the ELL2 promoter in both KMS11 and GM12878 using
promoter capture Hi-C (CHi-C) data. Within the active enhancer,
rs6877329 and rs3777184 fall within an overlapping genomic
fragment in both cell lines, forming a chromatin-looping interac-
tion with the ELL2 promoter (Figure 2; Table S4).
Effect of rs6877329 and rs3777184 Genotypes on
Enhancer Activity
To measure the effect of rs6877329 and rs3777184 alleles
on enhancer activity, we performed luciferase reporter assays
in KMS11. Transfection with constructs containing the
rs6877329-C risk allele displayed significantly lower normalized
luminescence compared to non-risk G-allele construct (two-
tailed t test p = 0.006, Figure 3A). rs3777184 genotype did not in-
fluence enhancer activity (two-tailed t test p = 0.57, Figure 3A).
These data are thus consistent with a model of MM risk in which
variation at rs6877329 is associated with decreased expression
of ELL2 (Table S5A). We next assayed protein-DNA interactions
for rs6877329-C and rs6877329-G alleles using an electropho-
retic mobility shift assay (EMSA). The G-allele formed stronger
protein-DNA complexes compared with the C-allele, consistent
with the region having differential transcription factor (TF) binding
(Figure 3B). From ENCODE chromatin immunoprecipitation
sequencing (ChIP-seq) data on GM12878, the CCAAT/
enhancer-binding protein beta (CEBPB) is the only TF overlap-
ping with rs6877329, albeit marginally. We did not, however,
demonstrate an EMSA super-shift with CEBPB antibody with
the G- and C-alleles (Figure 3B).L2. Genotyped (triangles) and imputed (dots) SNPs are shown based on their
alue on the y axis from (A) GWASmeta-analysis in UKMRCMyIX andMyXI trials
B) HRDMM (red) and non-HRDMM (blue) case-control meta-analysis in the UK
subjects, and 7,304 control subjects). Color intensity of each SNP reflects the
ecombination rates, estimated using HapMap samples of European ancestry,
to 5q15 are shown. rs1423269 and rs11372862 are annotated in black dotted
- brown dots represent p values for SNPs from the HRDMMcase-control meta-
es from the SMR test; lower panel - crosses represent eQTL p values of SNPs
8 Heidelberg GMMG patients (EMBL-EBI: E-MTAB-2299), with genes passing
. Probeset ID refers to Affymetrix U133 2.0 Plus Array custom chip definition file
Figure 2. Epigenetic Landscape at the 5q15 Locus
HRDMM (red) and non-HRDMM (blue) case-control meta-analysis as shown in Figure 1B. ChIP-seq from GM12878 (pink peaks), JJN3, KMS11, and L363 (black
peaks) are shown, annotated with the ChIP’d histone modification marks H3K4Me1, H3K4Me3, and H3K27Ac. DNaseI HS and ChromHMM data for GM12878
were assessed from ENCODE. A 8kb active enhancer (chr5:95,259,093-95,267,656) within ELL2 is shaded, predicted by ChromHMM, DNaseI HS, as well as
H3K4Me1, H3K4Me3, and H3K27Ac peaks. rs3777185, rs6877329, rs3777184, rs889302, rs2015159, and rs4563648 are localized within the enhancer with r2R
0.8 with rs11372862 (Table S3). Asterisk (*) marks the enhancer region interacting with the ELL2 promoter in both GM12878 and KMS11 (chr5:95,260,175-
95,264,576) encompassing rs6877329 and rs3777184. The positions of rs1423269, rs6877329, and rs3777184 are marked with black dotted lines.rs6877329 Risk Allele Is Not Preferentially Amplified in
Hyperdiploid Myeloma
Trisomy of chromosome 5 typifies HRDMM. To investigate a
possible relationship between heritable risk associated withrs6877329 and somatic mutation, we sought to determine
whether the risk C-allele, associated with reduced ELL2 expres-
sion, is preferentially amplified in HRDMM. We analyzed whole-
exome sequencing (WES) data on two independent series ofCell Reports 20, 2556–2564, September 12, 2017 2559
Figure 3. rs6877329 Is Associated with
Reduced Enhancer Activity and Differential
Nuclear Protein Binding
(A) rs6877329-C risk allele shows decreased
expression over the protective G-allele. Allele-
specific constructs containing a putative regula-
tory sequence flanking rs6877329 and rs3777184
were cloned into the pGL3 luc+ SV40-promoter
vector and transfected into KMS11. The ratio of
luminescence from the experimental pGL3-con-
structs to the Renilla internal control, pRL-SV40,
was normalized to the empty pGL3 luc+ SV40-
promoter vector. Data shown are mean ± SEM
from three independent experiments performed in
triplicate. Differences in gene expression were
assessed by the two-tailed t test.
(B) Electrophoretic mobility shift assay in
GM11992 showing differential nuclear protein
binding to alleles of rs6877329. Increased protein
binding observed for the non-risk G-allele. Asterisk
(*) indicates specific protein shift band.HRDMM tumors that were trisomic for chromosome 5 and het-
erozygous for rs6877329, using the highly correlated synony-
mous SNP rs3777204 and the missense SNP rs3815768 as
proxies (rs3777204 r2 = 0.99, D’ = 1.00; rs3815768 r2 = 0.95,
D’ = 0.99). rs3815768 is predicted to be benign and tolerated
by PolyPhen-2 and SIFT, respectively. After correcting for the
germline ratio of reference to alternate alleles in both series,
we found no evidence of preferential duplication of the risk
C-allele (Table S6).
ELL2 Expression Correlates with Unfolded Protein
Response and SEC Components
We sought to establish a possible functional consequence of
reduced ELL2 expression on MM oncogenesis. A recent study
of conditional knockout (cKO) ELL2 mice identified 10 genes
where loss of ELL2 expression resulted in at least a 2-fold differ-
ence in expression (Park et al., 2014). We assessed mRNA
expression correlation between ELL2 and these 10 genes in2560 Cell Reports 20, 2556–2564, September 12, 2017the tumors from 505 MM patients (GEO:
GSE21349 from the UK MRC MyIX trial;
EMBL-EBI: E-MTAB-372 from the
German GMMG trial). Although there
was no evidence for a trans-eQTL in BiP
(binding immunoglobulin protein), ATF6
(activating TF 6), ELL1 (elongation factor
for RNA polymerase II, 1), and POU2AF1
(POU class 2 associating factor 1) (Table
S5B), these genes consistently correlated
with ELL2 expression in MM (Figure 4).
Impact of rs6877329 Genotype and
Gene Expression on Patient
Prognosis
To examine the relationship between
rs6877329 genotype and ELL2 expres-
sion on patient outcome, defined by over-
all survival (OS) and progression-freesurvival (PFS), we made use of data from the UK MRC MyIX
and MyXI trials and the German GMMG trial, totaling 505 MM
patients with expression data and 2,553 patients with genotype
data. Meta-analysis of these data provided no evidence for an
association between either rs6877329 genotype or the level of
ELL2 expression with either OS or PFS (p > 0.4; Tables S7A
and S7B). We also found no evidence linking BiP, ATF6, ELL1,
and POU2AF1 expression to patient outcome (p > 0.2; Tables
S7C–S7F).
DISCUSSION
We acknowledge that the large LD block at 5q15 presents limita-
tions in prioritizing the functional variant underscoring the asso-
ciation. However, collectively our data demonstrate a plausible
mechanism underlying MM risk being mediated through
rs6877329, compatible with a differential effect on TF binding.
Moreover, data are compatible with the rs6877329-C allele
(legend on next page)
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conferring increased risk through reduced expression of ELL2.
Epigenetic and chromosome conformation capture data are
consistent with rs6877329 localizing within a chromatin contact
domain and overlapping a B cell enhancer. This interval forms a
‘‘loop domain,’’ bringing it into physical contact close to the tran-
scription start site of ELL2, separated by a linear distance of
around 35 kb.
ELL2 plays a key role in the differentiation ofmature B cells into
plasma cells (Park et al., 2014). ELL2 is induced 6-fold in plasma
cells and drives secretory-specific IgH mRNA production via
enhanced exon skipping and polyadenylation (Martincic et al.,
2009). B cell lineage ELL2 cKO mice show reduced numbers of
plasma cells and a paucity of secreted Ig (Park et al., 2014).
We have shown that individuals carrying the rs6877329-C risk
allele have reduced ELL2 transcript levels. The observation
that the MM risk locus at 5q15 is associated with reduced levels
of IgA and IgG in healthy individuals is thus consistent with a
hypomorphic effect associated with reduced ELL2 expression
(Swaminathan et al., 2015). These data do not lend themselves
to an obvious basis for allele-specific reduction in ELL2 being
associated with increased MM risk.
We observed a strong relationship between ELL2 with BiP
and ATF6 expression in MM. BiP is a regulator of the UPR
pathway during endoplasmic reticulum (ER) stress—a pathway
heavily relied on by MM plasma cells for survival due to its
active production and secretion of immunoglobulins (Vincenz
et al., 2013). BiP has been associated with the activation of
UPR inducers, such as ATF6, PERK (PKR-like ER kinase), and
IRE1 (inositol-requiring enzyme 1) (Bertolotti et al., 2000).
Furthermore, the UPR pathway regulates the equilibrium be-
tween proliferation and cell death during ER stress, and the
formation of autophagosome can be inhibited by BiP knock-
down (Li et al., 2008). Collectively, these data are compatible
with ELL2 having a role in the UPR and autophagy regulation
in MM through its interaction with BiP and ATF6. Importantly,
due to the pre-existing ER stress in MM plasma cells, such cells
are particularly prone to drug-induced ER stress by, for
example, the proteasome inhibitor bortezomib (Obeng et al.,
2006). ELL2 is also associated with ELL1 and POU2AF1 expres-
sion in MM patients, the latter being a transcriptional coactiva-
tor of OCT2 (octamer-binding protein 2), expression of which is
required for B cell differentiation (Hodson et al., 2016). Reduced
ELL2 expression associated with 5q15 thus potentially sug-
gests an impairment of SEC function and hindrance in plasma
cell development.
We did not observe an association between rs6877329 geno-
type or ELL2 expression level on patient survival in MM. While
our analysis had 80% power to demonstrate a 10% difference
in patient outcome at p = 0.05, we acknowledge that to detect
a smaller impact would require much larger patient cohorts. Ac-
cepting this caveat, our findings are consistent with differential
expression of ELL2 being important in the early phase of MM tu-
mor development rather than disease progression per se.Figure 4. Gene Expression Correlations with ELL2 in Multiple Myeloma
Expression correlation between ELL2 and BiP, and ATF6, ELL1, and POU2AF1 w
MM patients (EMBL-EBI: E-MTAB-372). Lines show linear regression fits. Expres
p values were combined from independent datasets using Fisher’s Method.
2562 Cell Reports 20, 2556–2564, September 12, 2017To directly inform of a possible relationship between the
rs6877329-C risk allele and somatic mutation, we exploited the
fact that the 5q15 association was primarily shown for HRDMM.
The effects of chromosome 5 gain are likely driven by a selective
advantage conferred by increased dosage of additional
unknown factors unrelated to the primary function of ELL2.
Evidence that HRDMM heterozygotes preferentially duplicate
the chromosome 5 homolog with the rs6877329-C risk allele
would have potentially suggested increased dosage of chromo-
some 5 gene expression relative to ELL2. Irrespective of a failure
to demonstrate such a relationship and although speculative, it is
possible that decreased ELL2 expression would increase the
probability of arrest of normal plasma cell development, facili-
tating MM clonal expansion. Since the association between
rs6877329-C risk allele and ELL2 expression is not exclusive to
HRDMM, these data suggest that loss of ELL2 activity is relevant
in the context of both HRDMM and non-HRDMM primary initi-
ating events.
In conclusion, we have shown reduced ELL2 expression in
MM patients carrying the rs6877329-C risk allele, thus providing
amechanistic basis for the 5q15 risk association for MM. Further
functional studies, however, are required to fully decipher
the biological basis of differential ELL2 expression on MM
oncogenesis.
EXPERIMENTAL PROCEDURES
Ethics
Collection of patient samples and associated clinico-pathological information
was undertaken with written informed consent and relevant ethical review
board approval at respective study centers in accordance with the tenets of
the Declaration of Helsinki, specifically, the MRC Leukemia Data Monitoring
and Ethics Committee (MREC 02/8/95, ISRCTN68454111, MREC 17/09/09,
and ISRCTN49407852) and the University of Heidelberg Ethical Commission
(229/2003, S-337/2009, AFmu-119/2010).
GWAS Data
The UK-GWAS and German-GWAS of MM have been previously reported
(Mitchell et al., 2016). The diagnosis of MM (ICD-10 C90.0) was established
in accordance with World Health Organization guidelines. All samples from
patients for genotyping were obtained before treatment or at presentation.
The UK-GWAS comprised 2,329 MM case subjects (1,060 male; mean age
at diagnosis: 64.0 years), including 702 with HRDMM, recruited through the
UK MRC MyIX and MyXI trials. Control subjects were provided by the Well-
come Trust Case Control Consortium 2 with 2,698 individuals in the 1958
British Birth Cohort and 2,501 individuals from the UK Blood Service. The
German-GWAS comprised 1,512 MM case subjects (867 male; mean age at
diagnosis: 59 years), including 661 with HRDMM. Case subjects were
recruited by theGMMG trial. Control subjects comprised 2,107 healthy individ-
uals from the Heinz Nixdorf Recall study. To recover untyped genotypes, we
performed imputation using IMPUTE2 v2.3 with a combined UK10K and
1000 Genomes Project (phase 1 integrated release 3, March 2012) panel for
reference (The 1000 Genomes Project Consortium, 2010; Huang et al.,
2015). Poorly imputed SNPs (INFO score < 0.80) were excluded. Frequentist
association testing between SNP genotype and MM was performed using
logistic regression under an additive genetic model in SNPTESTv2.5 (Marchini
et al., 2007). Meta-analysis was undertaken under a fixed-effects model usingas examined in 259 UK MM patients (GEO: GSE21349) and 246 German (GER)
sion correlation was assessed by Pearson’s product-moment correlation test.
inverse variance weighting in METAv1.7 (Marchini et al., 2007). To look for
independent effects, we performed conditional analysis with SNPTESTv2.5
with genotypes from UK and German GWAS individuals conditioning on
rs11376892. Logistic regression in case-only and case-control analyses was
used to assess tumor subtype.
Expression Quantitative Trait Loci Analysis
eQTL analyses were performed for genes and SNPs within 1 MB of
rs11372862 for CD138-purified plasma cells from 183 UK MyIX trial patients
and 658 German GMMG patients. Briefly, German and UK data were pre-pro-
cessed separately, followed by analysis using a Bayesian approach to proba-
bilistic estimation of expression residuals to infer broad variance components,
accounting for hidden determinants influencing global expression. The asso-
ciation between genotype of SNPs and expression of genes within 500 kb
either side of rs11372862 was evaluated based on the significance of linear
regression coefficients. We pooled data from the two studies under a fixed-ef-
fects model. Subtype-specific eQTL analyses were performed for ELL2, BiP,
ATF6, and POU2AF1 expression and rs11372862, rs1423269, and
rs6877329 for 170 UKMyIX trial and 602GermanGMMGpatients with subtype
and expression data. We carried out SMR analysis using previously estab-
lished methods (Zhu et al., 2016), with a threshold for the SMR test set at
PSMR < 0.00833 corresponding to Bonferroni correction.
ENCODE and Chromatin State Dynamics
To explore the epigenetic profile of association signals at 5q15, we used
DNaseI HS, TF ChIP-seq data, histone modifications (H3K4Me1, H3K4Me3,
and H3K27Ac), and ChromHMM in GM12878 from the ENCODE project
(ENCODE Project Consortium, 2012). ChIP-seq on H3K4Me1, H3K4Me3,
and H3K27Ac were carried out in KMS11, L363, and JJN3 cell lines.
In Situ Promoter Capture Hi-C
In situ promoter capture Hi-C libraries were prepared for KMS11 as previously
described (Rao et al., 2014). The interaction within ELL2 from its promoter with
the highest score was plotted. Promoter capture Hi-C on GM12878 was
obtained from EMBL-EBI: E-MTAB-2323 (Mifsud et al., 2015).
Plasmid Construction and Luciferase Assays
Regulatory region with rs6877329 and rs3777184 risk/non-risk alleles was
cloned into pGL3 luc+ SV40-promoter vector (Promega, Madison, WI, USA).
Reporter constructs were introduced into KMS11. Relative luciferase activity
was calculated as the ratio of luminescence from the experimental reporter
to the internal control plasmid (pRL-SV40). We calculated statistical signifi-
cance by using the two-tailed t test over three biological replicates.
Electrophoretic Mobility Shift Assay
Nuclear protein from GM11992 cells was incubated with infrared dye DY-682-
labeled double-stranded EMSA probes flanking rs6877329 (Eurofins
Genomics, Germany) (Supplemental Experimental Procedures). Competition
assays were performed by adding 100-fold molar excess of unlabeled probes.
Super-shifts were performed by adding 2 mg CEBPB antibody (sc-376591;
Santa Cruz Biotechnology, Texas, USA). DNA-protein complexes were
resolved by electrophoresis on a 6% DNA retardation gel (Life Technologies,
Carlsbad, CA, USA) in 1 3 Tris-borate-EDTA (TBE).
Gene Expression Analyses
We assessed the relationship between ELL2 and BiP, ATF6, POU2AF1, and
ELL1 gene expression (log2-transformed) in 259 UK MyIX clinical trial patients
and 246 German GMMG clinical trial patients using Pearson’s product-
moment correlation test. p values from the two patient datasets were com-
bined by Fisher’s Method. We conducted statistical tests using the R software
version 3.1.3.
Relationship between SNP Genotype and Somatic Copy Number
To investigate whether rs6877329was preferentially amplified in heterozygous
individuals with chromosome 5 trisomy, we analyzed WES data on 463 UK
MyXI trial cases (Walker et al., 2015) in conjunction with WGS and WES data
on 664 cases produced by the MM CoMMpass Study (Craig et al., 2013).57 and 50 hyperdiploid samples heterozygous for the risk variant with chromo-
some 5 trisomy were identified in the MyXI and CoMMpass datasets, respec-
tively. Given the counts of risk and non-risk reads sampled at two proxy coding
SNPs (rs3777204 and rs3815768, r2 > 0.95), each sample was assigned to its
most probable state (amplification of the risk or non-risk allele) assuming a
binomial distribution of counts and adjusting for reference mapping bias using
germline read counts.
Association between rs6877329 Genotypes, ELL2 Expression, and
Patient Outcome
The relationship between ELL2, BiP, ATF6, ELL1, and POU2AF1 expression
and patient outcome (OS and PFS) was assessed with 259 UK MyIX clinical
trial patients and 246 German GMMG clinical trial individuals grouped by their
ELL2 expression (upper and lower quartiles). Analysis was performed using the
log-rank test to estimate expression-associated hazard ratio and the 95%
confidence interval. Statistical tests were conducted using the R software
version 3.1.3. We assessed the relationship between rs6877329 genotype
and patient outcome using GWAS data on (1) 1,165 patients in the UK
GWAS from the MyIX trial, (2) 877 MM patients in the UK GWAS from the
MyXI trial, and (3) 511 of the patients in the German GWAS from the GMMG
clinical trial. Cox regression analysis was used to derive genotype-specific
hazard ratio and associated 95% confidence intervals.
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